 | | Check Your Emotions at the Door: A Good Story Does Not Make a Good Investment | | Marc Lichtenfeld, Chief Income Strategist, The Oxford Club | What the %$#! Is This $5 5G stock?
It works with Chevron, Cisco, Uber, Amazon and Wells Fargo.
It counts the U.S. Army and Department of Homeland Security as customers.
Vanguard, BlackRock, J.P. Morgan, Goldman Sachs and Citigroup have all taken HUGE positions.
And company insiders are loading up on TONS of shares.
This $5 stock could be the linchpin of the 5G revolution. The incredible story is here. | | | Editor's Note: As Marc writes in today's essay, when it comes to investing, a good story alone is not enough to make a stock lucrative.
Fundamentals are key - so investors who want to profit must stay objective.
This is especially true in the biotech sector. Often, investors exploring the space will get caught up in a compelling story - and will shell out their savings without asking the tough questions.
Marc's watched this happen to too many investors - so now he's fighting back.
Marc is an expert in biotech investing, and he developed his Lightning Trend Trader system to help investors identify high-potential opportunities in the healthcare sector.
He connects his readers to companies that save lives... while still turning a profit.
(In the past, these profits have skyrocketed as high as 2,381%...)
Click here to learn how you can enter one of the market's most compelling sectors without playing with fire.
- Mable Buchanan, Assistant Managing Editor
When it comes to picking stocks, some investors study a company's fundamentals. These include ratios like price-to-earnings, price-to-sales and price-to-book, as well as the cash flow statement.
Others prefer to analyze a stock's technical aspects, looking at moving averages and support and resistance levels so they can weigh the best time to buy.
But with some stocks, it's not the fundamental or technical aspects that take center stage. It's the story... | | | | Question of the Week | | While working, how much of your income did you (or do you) allocate to savings each month?
Click here to answer. | | Saving Lives... Making Money
This is often the case with healthcare stocks - particularly the smaller names. And it's not surprising that investors get excited about owning shares of companies with potential breakthrough drugs.
After all, who wouldn't want to be involved with companies that are saving people's lives or relieving suffering? At a cocktail party, do you want to talk about the S&P 500 or the $2 stock that could go to $50 if its cancer drug is approved?
It's compelling stuff.
When I first was licensed as a Wall Street analyst, I covered retail stocks. Being a stock junkie, it was interesting. But after a while, same-store sales figures didn't provide that rush I craved. I needed more.
Biotech provided it.
I'm half joking here. You should never invest in stocks because you need the adrenaline rush. But being a writer, and also an analyst, I always wanted to tell a story as well as crunch the numbers.
But here's one of the downsides of a "good story" - and what to do when you become too attached to its stock...
You Hear That Voice? It's the Voice of Reason
The primary reason for buying companies with feel-good stories is because investors want the story to result in a higher share price - and in turn, produce a sizable profit when they sell the stock.
But when you become too attached to the story at the expense of reason, not selling the stock can prove disastrous.
Sometimes we're blind to evidence that the company or drug isn't all it's cracked up to be. Other times, we ignore our trailing stop discipline because we just can't let go of the story.
The Mela Emotional Investing Story
I advised the subscribers to one of my services to buy shares of Mela Sciences on two different occasions.
- In March 2010, we grabbed a 42% gain on the stock.
- And when it fell, we bought on the dip and cashed in another 39% gain in June.
The company made a device called MelaFind, which tells doctors whether they need to biopsy for melanoma.
By June 2010, Mela Sciences had concluded Phase 3 trials on the device and planned for a Food and Drug Administration (FDA) panel review in August. The panel would then recommend to the FDA whether MelaFind should be approved.
If the FDA determined that MelaFind was effective and approved it, the device would save a lot of lives, as it would detect melanomas that physicians might otherwise miss.
But I advised my readers to pull the trigger and sell the stock. | | | | How to Retire Starting With $20 Bill O'Reilly and a legendary stock picker just revealed the only way to retire rich starting with $20. Details here. | | | It was a tough decision. I had followed the company for several years. I personally liked the CEO at the time and believed he was firmly committed to saving lives.
But I wasn't confident in this market catalyst. And by the time the FDA delayed premarket approval for MelaFind in August, the stock was 50% below its 52-week high.
The stock suffered more volatility in November as it was criticized but ultimately approved by the FDA. But even finally hearing this good news, Mela investors were so wary of the roller coaster that in the end, they were ambivalent.
In 2015, MelaFind was recalled and Mela rebranded to Strata Skin Sciences (Nasdaq: SSKN).
In short, Mela Sciences' story was as good and emotional as it gets. And by buying at the right time, we did nab a sizable gain. But when it comes to investing, emotions are dangerous.
Two Quick Steps to Becoming a Cold-Blooded Investor
When I came across some new information that made me question my original investment thesis, I couldn't ignore it.
After issuing the sell recommendation, I wasn't surprised to receive some emails from people saying they were going to hang on because they still believed in the company.
When I receive feedback like this from readers, I hope they make a million dollars because that would mean that lives are being saved. And if I fail to present a convincing argument against a stock, that's my fault.
But if they're holding on to the stock for no reason other than that they've become so emotionally invested in the story, that's a recipe for disaster.
So if you're holding shares of companies that have compelling stories and have an emotional component, take the following steps...
- Set a trailing stop: We've said it here many times before - and for good reason. Doing so makes the sell decision an automatic one and removes all emotion from the process.
- Phone a friend: Every so often, tell the stock's story to someone who knows nothing about it. See what their reaction is. Listen to their questions. First, see if you can answer them and then see how well you can answer.
Seeing it through the eyes of someone who isn't already emotionally involved and has money on the line may reveal issues that you hadn't thought of (or chose to ignore). In conclusion, let other investors' emotions fuel the run-up in your stocks. Just be sure to keep yours in check so that you can get out while the gettin's still good.
Good investing,
Marc
P.S. When it comes to identifying the best opportunities in the market, it's crucial to be precise - not shoot from the hip.
Companies that help cure rare diseases - the kind I recommend to readers of my Lightning Trend Trader - are going to be some of the market's biggest winners over the coming years.
In fact, my favorite players in the healthcare sector will hand investors gains of 3,000% or more.
Why am I so positive? In addition to having a great story, these companies have the acumen and technological power to back it up.
Click here to learn more. | | | | | | Uncovered: Blowing the Whistle on the "Democratic Socialists"
 We've uncovered controversial facts concerning Alexandria Ocasio-Cortez... Kamala Harris... Elizabeth Warren... and several of their socialist "comrades."
These findings could change the course of the 2020 elections... if not the ENTIRE U.S. political landscape.
(In an odd twist, this evidence could also help YOU collect a good deal of cash.)
Our investigative team went to Washington, D.C., to get the scoop. To see our SHOCKING, EXCLUSIVE video, just click here. | | | | - More From Wealthy Retirement - | | | | | | | | | [REVEALED] Your Body's Secret System
In the 1990s, a team of Israeli scientists made a shocking discovery. They found proof of a secret 12th system in the human body.
If it isn't working properly, you could be at greater risk for Alzheimer's... heart disease... arthritis... and even cancer. But there's a natural "divine medicine" that helps it work at its best.
GO HERE now. | | | | | |
The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. 
No comments:
Post a Comment